ArrowHead Pharma
ARWR----
ArrowHead Pharma (ARWR)
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce pr...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
ArrowHead Pharma Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$104.2719.80%
Forecast & RatingStrong buy
12analysts
- Strong buy66.67%
- Buy33.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · 3 hours ago
This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Monday
- StockTitan · 11 hours ago
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia | ARWR Stock News
- rttnews · Jul 22 at 10:15 PM
Top Biotech Gainers: ZCMD Surges 190%, LABT Advances On Nu-3 Progress, ARWR Hits The Targets
- TradingKey · Jul 22 at 03:17 PM
Arrowhead Pharmaceuticals Inc Stock (ARWR) Closed Up by 19.04% on Jul 22: What Signal Does It Send?
- Market Beat · Jul 22 at 02:36 PM
Chardan Capital Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock
- US Stock Market Update · Jul 22 at 02:13 PM
Arrow Pharmaceuticals soars 22% on strong Phase 3 lipid drug results
